TFF Pharmaceuticals, Inc.

NASDAQ
TFFP
paper.types.company
Rentabilité sur six mois: -78.69%
Rendement en dividendes: 0%
Secteur: Healthcare

0.065 $

0 $ 0%
0.065 $
2.65 $

paper.min_max_per_year

Calendrier des promotions TFF Pharmaceuticals, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.

plus de détails
The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2019-10-25
ISIN
US87241J1043
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 17.12 1
P/BV 1.31 9
P/E 0 0
Efficacité
Nom Signification Grade
ROA -176.62 0
ROE -222.05 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.0052 10
Debt/Ratio 0.0096 10
Debt/Equity 0.2572 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 72.84 8
Rentabilité EPS, % 597.11 10
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 0.065 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 0.065 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.30d 0.065 $ 0.065 $ 0.065 $ 0 % 0 % 0 %
common.calendar.number_days.90d 0.065 $ 0.065 $ 0.065 $ 0 % 0 % 0 %
common.calendar.number_days.180d 0.305 $ 0.065 $ 0.1627 $ -78.69 % 0 % 0 %
common.calendar.number_days.1y 2.05 $ 0.065 $ 2.65 $ -96.83 % 0 % 0 %
common.calendar.number_days.3y 5.78 $ 0.065 $ 200 $ -98.88 % 0 % 0 %
common.calendar.number_days.5y 5 $ 0.065 $ 200 $ -98.7 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.065 $ 200 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 0.065 $ 0.065 $ 0.065 $ 0 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Harlan F. Weisman President, CEO & Director 742.5k 1952 (73 année)
Mr. Kirk Allen Coleman CFO, Treasurer & Secretary 409.94k 1974 (51 année)
Dr. Zamaneh Mikhak M.D. Chief Medical Officer 545.38k 1964 (61 année)

Informations sur l'entreprise

Adresse: United States, Fort Worth. TX, 1751 River Run - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://tffpharma.com